Arctic Bioscience - Regulatory Filings 2023

Arctic Bioscience - More than 75% recruited in the phase IIb HeROPA clinical trial

With reference to the Q3 update from November 2[nd] 2023 which reported more

than 50% recruited patients to the phase IIb clinical trial HeROPA, Arctic

Bioscience is pleased to report that we have now recruited more than 75% of the

patients required for the trial.

The HeROPA phase IIb clinical trial of HRO350 - a novel, oral drug candidate for

the treatment of mild-to-moderate psoriasis - is ongoing in 5 countries in

Europe; UK, Germany, Poland, Finland and Norway. As planned, recruitment speed

has increased throughout fall as new clinics have been activated. Recruitment is

going particularly well in Germany and Poland.

A total of 519 patients are to be included in the trial. To date, more than 75%

of the needed patients have been recruited.

"We are very pleased about the current recruitment speed in our HeROPA clinical

trial, which brings us closer to our estimated mid 2024 data read-out." says CEO

Christer L. Valderhaug.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.

AI assistant